Clinical observation of Nab-paclitaxel on patients with advanced pancreatic carcinoma who failed to gemcit-abine first-line therapy
MEI Kuimin
LIU Xiufeng
GONG Xinlei
FANG Rong
ZHANG Jue
LI Hui
YAO Lin
QIN Shukui
Abstract：Objective To evaluate the efficacy and safety of Nab?paclitaxel ( Nab?P ) on patients with advanced pancreatic carcinoma who failed to gemcitabine first?line therapy. Methods Patients with advanced pancreatic carcinoma who have failed to first?line therapy from May 2012 to May 2015 were analyzed retrospectively. All the patients received Nab?P?based monotherapy or combina?tion regimens( Nab?P 110 mg/m2 iv, d1 ,d8 , every 3 weeks) as second or more line treatments. The efficacy and safety were evaluated by RECIST 1?1 and NCI?CTC 4?0 criteria. Median time to disease progression(TTP) and overall survival(OS) were analyzed by Kap?lan?Meier method. Results Thirteen patients failured to gemcitabine?based regimen were enrolled and 9 of them were evaluatable. The median age was 56?1 years, and the average treatment cycle was 2?27. The disease control rate( DCR) was 55?6%, including 2 cases of PR, 3 cases of SD and 4 cases of PD. The number of patients with elevated baseline CA19?9 had>50% decline was 4(44?4%). The median TTP was 3?0 months(95%CI: 2?4?4?2 months) and the median OS was 14?2 months(95%CI: 2?8?25?6 months).The 3?month and 6?month survival rate was 88?9% and 77?8%, respectively. The major treatment?related side effects including leucopenia, neutropenia, nausea, vomiting, fatigue and etc. were mainly in grade 1?2. Conclusion Nab?paclitaxe is effective and tolerable in Chi?nese advanced pancreatic carcinoma patients who have progressed on gemcitabine first?line therapy.
Keywords：Nab-paclitaxel(Nab-P)Advanced pancreatic carcinomaSecond-line chemotherapy
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 913-917 )